Genetic differences in genetic structures are influential on the goodness or side effects of drugs as they are discarded from the body after being metabolized. Therefore, with the help of pharmacogenetic tests applied prior to treatment; hypersensitivity, unresponsiveness to the treatment and, evident side effect can be pre determined. Dose adjusments and regulations can be assigned, as well.

In our center, molecular genetic analysis can be performed for   CYP2C9, CYP2C19, CYP2D6 and 5-HTT gene regions which are thought to play an effective role on many widely used antipsychotic drugs like warfarin and clopidogrel.

Recently, many target oriented new drugs have been developed for cancer treatment. Pharmacogenetic tests are important in determinining for which patients these newly discovered drugs provide significant benefits in the treatment of cancer. Genetic tests have been applied routinely prior to usage of drugs which are particularly developed for treatment of breast, colon, lung cancers and gastrointestinal tumors (GIS) as well as malignant melanomas.

Required pharmacogenetic tests in order to determine HER2, ALK-EML4, ROS1, PDL1&2, EGFR, KRAS, NRAS, BRAF, C-KIT and PDGFRA mutations can be performed in our center. These tests are frequently requested by physicians.